BCRX Earnings Prediction
The chart below shows how BCRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BCRX sees a +2.24% change in stock price 10 days leading up to the earnings, and a +1.43% change 10 days following the report. On the earnings day itself, the stock moves by +0.04%. This data can give you a slight idea of what to expect for the next quarter's release.
BCRX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
117.08M
34.98%
7.09%
Gross Margin
97.24%
-1.47%
-1.19%
Operating Margin
6.57%
147.82%
-17.98%
Net Margin
-11.99%
-71.23%
3.45%
EPS
-0.07
-63.16%
16.67%
No Data Available
BCRX Earnings Analysis
BioCryst Pharmaceuticals Inc Corporation (BCRX.O) Earnings Conference Call
Positive
Impressive Revenue Growth: Growing ORLADEYO quarterly revenue year-over-year by nearly 36%, now four years from approval is amazing.
Quarterly Operating Profit: We achieved an operating profit for the quarter of $24.9 million, excluding non-cash stock comp, and even when including non-cash stock comp, we made an operating profit of $7.7 million.
Cash Flow Improvement: Cash at the end of the quarter was up $351.7 million and we had positive net cash flow for the quarter of over $13 million.
Revenue Guidance Adjustment: We are tightening our revenue guidance for 2024 to $430 million to $435 million, the upper end of our prior range.
RAPIVAB Revenue Expectations: We expect to see significant near-term revenues for RAPIVAB, with nearly $7 million in API orders for our Southeast Asia partners for Q4.
Negative
Quarterly Revenue Overview: Total revenue for the quarter was $117.1 million, with $116.3 million of that coming from ORLADEYO, indicating a slight decline in growth compared to previous quarters.
Operating Expenses Increase: Operating expenses, not including non-cash stock compensation for the quarter were $92.2 million, which is a significant increase from prior periods.
Operating Expenses Impact Profitability: GAAP operating expenses came in at $109.4 million, reflecting higher costs that could impact profitability.
Operating Profit Analysis: The company achieved an operating profit for the quarter of $24.9 million, excluding non-cash stock compensation, which is lower than expected given the revenue growth.
Cash Flow Concerns: Cash at the end of the quarter was up $351.7 million, but the company is expecting cash flow to be negative in Q4 and Q1, indicating potential liquidity issues.
BCRX FAQs
How does BCRX typically perform around its earnings report dates?
Is BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BCRX Earning Call Sentiment
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BCRX.O
-1.92%Positive
The earnings call highlights strong financial performance with a 36% YoY revenue growth for ORLADEYO and positive cash flow, despite challenges such as supply chain issues and competition. Increased revenue guidance and a commitment to profitability are positive indicators. The Q&A section reveals optimism about future growth and managing competition. The lack of a shareholder return plan is offset by a strong cash position. Given the company's market cap and positive financial outlook, the stock price is likely to see a positive movement of 2% to 8% over the next two weeks.
